查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947178

雙環肽市場按產品類型、治療領域、技術平台、給藥途徑、應用、最終用戶和銷售管道，全球預測，2026-2032年

Bicyclic Peptide Market by Product Type, Therapeutic Area, Technology Platform, Route Of Administration, Application, End User, Sales Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年雙環肽市場規模為3.8547億美元，預計到2026年將成長至4.3477億美元，複合年成長率為14.34%，到2032年將達到9.8547億美元。

關鍵市場統計數據
基準年 2025 3.8547億美元
預計年份：2026年 4.3477億美元
預測年份 2032 9.8547億美元
複合年成長率 (%) 14.34%

權威的介紹說明了雙環肽在現代治療藥物開發中的地位，並解釋了它們獨特的分子優勢和潛在的臨床應用。

雙環肽是一類新興的受限胜肽類藥物，它兼俱生物製藥的特異性和促進組織穿透及口服滲透性的理化性質。其由兩個共用橋連接的拓撲結構限制了3D空間構型，增強了抗蛋白酶穩定性，並且與線性胜肽相比，通常能提高靶向親和性。這些特性使雙環肽成為治療複雜標靶（例如蛋白質-蛋白質相互作用和膜相關受體）的多功能配體，而傳統小分子和單株抗體在這些標靶上面臨挑戰。

科學、技術和商業性變革正在迅速改變雙環肽藥物的發現、開發和產業合作。

雙環肽領域正因多方面技術的融合進步而重塑：展示技術能夠更深入地探索化學多樣性，連接基團化學能夠產生更易於成藥的骨架，而分析能力的提升則降低了候選藥物篩選的風險。這些因素正推動研究方向從探索性研究轉向以管線主導的專案開發，強調能夠大規模提供可重複先導化合物系列的模組化平台。

2025年關稅趨勢對雙環肽供應鏈、籌資策略和產業合作模式的累積營運和策略影響

近期關稅政策的變化，為依賴國際供應鏈獲取試劑、客製化肽以及用於雙環肽合成和生產的特殊組件的企業，增添了戰略上的複雜性。關稅正在改變供應商的經濟格局，促使採購團隊重新評估採購模式，並更加重視供應鏈透明度和多源檢驗。對於依賴快速取得化學多樣性庫和展示試劑的藥物研發企業而言，上游供應鏈的中斷和成本壓力可能會延緩迭代週期，並增加專案風險。

全面的細分洞察，闡明應用、治療領域、產品類型、技術平台、給藥途徑、最終用戶和銷售管道如何相互作用，從而指導您的策略。

一個穩健的細分框架揭示了雙環肽生態系統的不同維度如何相互作用，從而影響藥物發現的優先順序和商業化路徑。從應用領域來看，該領域的研究活動主要集中在診斷、藥物發現和治療方面。在治療領域，相關項目主要集中於心血管疾病、感染疾病和腫瘤，其中腫瘤研究進一步細分為血液腫瘤和固態腫瘤。這種層級式的觀點有助於解釋為什麼某些藥物發現投資側重於高親和性限制性配體，而另一些則側重於用於診斷劑開發的快速、低成本篩檢方案。

提供具有區域針對性的情報，闡釋美洲、歐洲、中東和非洲以及亞太地區如何各自塑造創新、監管、製造和商業化的動態。

區域趨勢對創新模式、監管預期和商業化策略有顯著影響。細緻入微的觀點對於策略規劃至關重要。在美洲，強大的學術生態系統和蓬勃發展的生物技術產業推動了早期轉化研究和商業性夥伴關係。監管機構傾向於優先考慮高需求治療方法的快速核准途徑，而大規模合約研發生產機構（CDMO）的存在則為有前景的候選藥物的規模化生產提供了支持。這種環境促進了從發現到早期開發之間的快速迭代，但也需要製定清晰的證據生成計劃，以確保獲得投資和夥伴關係承諾。

提供可操作的企業級洞察，揭示平台差異化、夥伴關係模式和營運嚴謹性如何決定企業領導地位和長期競爭優勢。

在雙環肽領域，企業的行為將受到平台差異化、策略合作和有針對性的研發投資等因素的共同影響。該領域的領導企業往往提供清晰的平台價值提案，例如卓越的化合物庫多樣性、快速的篩選週期或獨特的連接基團化學，從而賦予候選藥物差異化的特性。將專有的藥物發現平台與可擴展的合成和分析流程相結合的企業，能夠透過縮短開發週期和提高專案間的可重複性，創造永續的競爭優勢。

為領導者提供切實可行的高影響力建議，以建立務實的合作關係，加速雙環肽項目，加強供應鏈，並降低研發風險。

行業領導者應採取一套綜合措施，在加快藥物研發的同時降低營運和監管風險。首先，他們應將資源集中於具有高臨床潛力的候選藥物，使藥物研發的優先事項與治療目標和臨床可行性一致。這需要藥物化學家、結構生物學家、轉化藥理學家和監管專家之間的跨學科合作，以便儘早確定目標產品特性，並識別影響連接子和支架選擇的生產過程限制因素。

本文介紹了一種透明的調查方法，說明如何結合一手訪談、二手文獻和交叉檢驗方法，以獲得對雙環肽的可靠見解。

支持這些發現的研究結合了精選的一手和二手資料，以確保研究的深度和多方驗證。一級資訊來源包括對藥物研發科學家、轉化藥理學家、採購人員和直接參與受限胜肽類藥物研發的業務拓展主管進行的結構化訪談。這些訪談提供了關於平台功能、營運限制和合作理由的定性背景資訊。二級資訊來源整合了同行評審文獻、專利概況、監管指導文件以及平台提供者的技術應用說明，以檢驗在一手訪談中觀察到的趨勢。

一項關鍵的綜合分析，旨在提煉戰略要務，並優先考慮近期行動，以將雙環肽創新轉化為臨床進展和商業性成果。

全面的證據表明，這種療法已進入戰略成熟階段。雙環肽如今已成為解決複雜生物標的的可靠選擇，支持其發現和開發的生態系統也已發展到足以推動轉化研究的程度。展示技術和連接子化學的科學進步，結合更先進的轉化工具包，降低了胜肽類藥物研發的一些傳統障礙，並實現了更具針對性的專案設計。同時，供應鏈韌性、監管溝通和合作夥伴選擇等營運和商業因素在決定推進哪些項目方面也變得日益重要。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 雙環肽市場（依產品類型分類）

  • 雙環胜肽
    • 醯胺連接基
    • 酯連接基
    • 硫醚連接基
  • 線性胜肽
  • 單環胜肽
  • 多環胜肽

9. 雙環肽市場依治療領域分類

  • 循環系統疾病
  • 感染疾病
  • 發炎性疾病
  • 腫瘤學

10. 雙環肽市場（依技術平台分類）

  • mRNA展示
  • 噬菌體展示
  • 分池
  • 酵母展示

第11章 雙環肽市場（依給藥途徑分類）

  • 吸入
  • 注射
    • 肌肉內注射
    • 靜脈注射
    • 皮下注射
  • 口服
  • 外用

第12章 雙環肽市場依應用領域分類

  • 診斷
  • 藥物發現
  • 治療藥物
    • 心血管疾病
    • 感染疾病
    • 腫瘤學
      • 血癌
      • 固態腫瘤

第13章 雙環肽市場（依最終用戶分類）

  • 學術和研究機構
  • CRO（受託研究機構）
  • 製藥和生物技術公司
    • 大型製藥企業
    • 新興生技公司

第14章 雙環肽市場銷售管道

  • 線上
  • 離線

15. 雙環肽市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 雙環肽市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國雙環肽市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國雙環胜肽市場

第19章：中國雙環胜肽市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bicycle Therapeutics plc
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • PeptiDream Inc.
  • Pfizer Inc.
  • Sanofi
  • Servier Laboratories
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-4F7A6D4FB5FA

The Bicyclic Peptide Market was valued at USD 385.47 million in 2025 and is projected to grow to USD 434.77 million in 2026, with a CAGR of 14.34%, reaching USD 985.47 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 385.47 million
Estimated Year [2026] USD 434.77 million
Forecast Year [2032] USD 985.47 million
CAGR (%) 14.34%

An authoritative introduction that positions bicyclic peptides within contemporary therapeutic discovery and explains their unique molecular benefits and translational relevance

Bicyclic peptides are emerging as a distinctive class of constrained peptide therapeutics that combine the specificity of biologics with physicochemical properties that can favor tissue penetration and oral permeability. Their structural topology, defined by two covalent bridges that constrain conformation, provides enhanced proteolytic stability and often augments target affinity versus linear counterparts. These attributes position bicyclic peptides as versatile ligands for challenging targets, including protein-protein interactions and membrane-associated receptors, where traditional small molecules and monoclonal antibodies face limitations.

Advances in chemical linkers and conjugation strategies have broadened the toolkit available to discovery teams, enabling rational optimization of pharmacokinetic and biodistribution profiles. At the same time, improvements in high-throughput selection platforms have accelerated hit identification cycles, enabling parallel exploration of diverse chemical space. Taken together, these developments have moved bicyclic peptides from a predominantly academic curiosity toward a modality with tangible translational potential. In this context, investors, program leaders, and translational scientists are increasingly treating bicyclic peptides as a credible option when designing differentiated pipelines for oncology, infectious disease, and other high-unmet-need therapeutic areas.

As the field matures, careful attention to downstream considerations-manufacturing robustness, regulatory pathways, and formulation strategies-becomes as important as early-stage potency and selectivity. Consequently, stakeholders must adopt an integrated view that aligns discovery innovation with pragmatic development planning to realize the modality's promise in patients.

Transformative scientific, technological, and commercial shifts that are rapidly changing how bicyclic peptides are discovered, developed, and partnered across the industry

The bicyclic peptide landscape is being reshaped by convergent advances on multiple fronts: display technologies are enabling deeper exploration of chemical diversity, linker chemistry is producing more drug-like scaffolds, and improved analytical capabilities are de-risking candidate selection. These forces are catalyzing a shift from exploratory research toward pipeline-driven program development, with an emphasis on modular platforms that can deliver reproducible lead series at scale.

On the technological front, next-generation selection methods have expanded accessible diversity, reducing attrition during hit-to-lead transitions. Concurrently, innovations in synthetic chemistry and bioconjugation provide medicinal chemists with greater control over pharmacokinetic tuning and cell permeability. This combination of selection precision and chemical tractability has increased confidence among program leaders to pursue challenging targets, including intracellular protein-protein interactions that previously eluded conventional modalities.

Commercially, discovery-stage alliances and platform licensing models are evolving. Biotech companies are packaging display and screening capabilities as partnership-ready assets, while larger pharmaceutical organizations are adopting flexible collaboration frameworks to accelerate access to novel hits. Regulatory authorities are also adapting to the unique attributes of constrained peptides, which encourages earlier engagement and more predictable development pathways. Collectively, these shifts are transforming bicyclic peptides from niche research themes into a practical, investable modality within contemporary drug discovery portfolios.

Cumulative operational and strategic implications of 2025 tariff developments on bicyclic peptide supply chains, sourcing strategies, and collaborative models across the sector

Recent tariff policy developments have introduced a new layer of strategic complexity for organizations that rely on international supply chains for reagents, custom peptides, and specialized components used in bicyclic peptide discovery and manufacturing. Tariffs can alter supplier economics and prompt procurement teams to re-evaluate sourcing patterns, placing a premium on supply chain transparency and multi-source validation. For discovery-oriented operations that depend on rapid access to chemically diverse libraries and display reagents, any disruption or cost pressure in the upstream supply base can slow iteration cycles and increase program risk.

In response, many organizations have begun to reassess inventory strategies, prioritize domestic or tariff-exempt suppliers for critical inputs, and invest in redundant manufacturing capabilities where feasible. These adjustments often require cross-functional coordination among procurement, legal, and scientific teams to ensure continuity without compromising experimental throughput. Additionally, changes in trade policy can influence collaborative transaction structures; companies may opt for in-kind research partnerships or local contract development relationships to sidestep cross-border tariff exposure.

The cumulative effect is a heightened emphasis on supply chain resilience, with leaders placing greater value on supplier audits, geographic diversification, and inventory hedging. While tariffs can increase near-term operational complexity, they also incentivize investment in localized capabilities, which over time can yield shorter lead times and greater control over quality. Strategic planning that anticipates these dynamics and aligns sourcing decisions with program timelines will be crucial for maintaining momentum in bicyclic peptide research and development.

Comprehensive segmentation insights that clarify how application, therapeutic area, product type, technology platform, administration route, end user, and sales channels interact to guide strategy

A robust segmentation framework reveals how different axes of the bicyclic peptide ecosystem interact to shape discovery priorities and commercial pathways. When the field is viewed through the lens of application, activity clusters around diagnostics, drug discovery, and therapeutics; within therapeutics, programs focus on cardiovascular diseases, infectious diseases, and oncology, with oncology efforts further differentiated into hematologic cancers and solid tumors. This layered perspective helps explain why certain discovery investments favor high-affinity constrained ligands while others emphasize rapid, low-cost screening solutions for diagnostic reagent development.

Therapeutic-area segmentation highlights where modality fit is strongest, showing significant alignment between bicyclic peptide properties and targets in cardiovascular, infectious, inflammatory disorders, and oncology indications. These disease classes influence target selection criteria, safety expectations, and clinical development strategies, thereby shaping discovery throughput and translational decision-making. In turn, product-type segmentation underscores the comparative advantages among bicyclic peptides, linear peptides, monocyclic peptides, and multicyclic peptides; within bicyclic chemotypes, choice of linker chemistry-such as amide, ester, or thioether linkers-affects stability, synthetic tractability, and the downstream manufacturing pathway.

Technology platform segmentation draws attention to methodological differentiation: platforms like mRNA display, phage display, split-and-pool, and yeast display each bring distinct capabilities and constraints; for example, phage display itself can be parsed into M13 and T7 systems that vary in library presentation and amplification dynamics. Route-of-administration segmentation-spanning inhalation, injectable, oral, and topical modalities-further narrows development priorities, with injectable approaches subdivided into intramuscular, intravenous, and subcutaneous strategies that impose differing formulation and safety considerations. End-user segmentation captures the ecosystem of academic and research institutes, contract research organizations, and pharmaceutical and biotechnology companies, the latter of which ranges from large established pharmaceutical firms to early-stage biotech innovators. Finally, sales-channel segmentation from direct sales to distribution partners and e-commerce, with e-commerce differentiating between marketplaces and vendor websites, informs commercial planning and access strategies for supporting technologies and reagent providers. By synthesizing these segmentation axes, stakeholders can better prioritize platform investments, tailor development pathways to therapeutic intent, and align commercial models with end-user purchasing behaviors.

Nuanced regional intelligence explaining how the Americas, Europe Middle East & Africa, and Asia-Pacific each shape innovation, regulation, manufacturing, and commercialization dynamics

Regional dynamics substantially influence innovation patterns, regulatory expectations, and commercialization approaches, and a regionally nuanced view is essential for strategic planning. In the Americas, academic ecosystems and a vibrant biotechnology industry drive early translational activity and commercial partnerships; regulatory engagement tends to emphasize accelerated pathways for high-need therapies, and the presence of large contract development and manufacturing organizations supports scale-up for promising candidates. This environment facilitates rapid iteration between discovery and early development but also demands clear evidence generation plans to secure investment and partnership commitments.

Europe, Middle East & Africa present a diverse regulatory and funding landscape with pockets of excellence in peptide chemistry and strong academic-industry consortia that advance platform innovation. Regulatory frameworks across this region encourage harmonization while allowing national-level variation that affects trial design and market access strategies. Collaboration across countries in this region often emphasizes public-private partnerships and consortium models that can accelerate precompetitive development and shared infrastructure initiatives.

Asia-Pacific combines manufacturing scale, growing R&D capacity, and increasingly sophisticated biopharma ecosystems. The region offers strategic advantages in cost-effective production and rapid manufacturing scale-up, which can be critical for companies moving from lead identification to clinical supply. Regional regulatory maturation and expanded clinical trial capabilities also make Asia-Pacific an attractive region for global development programs, particularly when combined with localized commercial strategies that account for reimbursement frameworks and patient access mechanisms. Recognizing these regional distinctions enables companies to localize procurement, regulatory engagement, and partnership strategies to optimize development timelines and commercialization readiness.

Actionable company-level insights that reveal how platform differentiation, partnership models, and operational rigor determine leadership and long-term competitiveness

Company behavior in the bicyclic peptide domain is shaped by a mix of platform differentiation, strategic collaboration, and targeted R&D investment. Leaders in this space tend to articulate clear platform value propositions, such as superior library diversity, rapid selection cycles, or unique linker chemistries that enable differentiated candidate properties. Organizations that combine proprietary discovery platforms with scalable synthetic and analytical pipelines create durable competitive advantages by shortening development timelines and improving reproducibility across programs.

Partnership strategies differ by organizational maturity. Early-stage companies often pursue co-development or licensing relationships to access late-stage regulatory expertise and commercial channels, while larger companies pursue bolt-on acquisitions and strategic alliances to internalize novel platforms. Intellectual property strategies focus on protecting core platform innovations and inventive linker or conjugation approaches while maintaining freedom to operate for downstream therapeutic use. In parallel, companies increasingly emphasize reproducible manufacturing processes and quality-by-design principles to smooth the transition from discovery to GMP production.

Operationally, successful companies invest in multidisciplinary teams that bridge chemistry, structural biology, and translational pharmacology to reduce the risk of attrition. They also prioritize early regulatory engagement to clarify nonclinical and clinical expectations for constrained peptide modalities. Together, these practices enable firms to convert scientific novelty into clinically and commercially viable programs with higher predictability.

High-impact, actionable recommendations for leaders to accelerate bicyclic peptide programs, strengthen supply chains, and structure pragmatic collaborations to de-risk development

Industry leaders should adopt an integrated set of actions to accelerate development while reducing operational and regulatory risk. First, aligning discovery priorities with therapeutic intent and clinical feasibility will concentrate resources on candidate profiles that are most likely to translate. This requires cross-functional alignment among discovery chemists, structural biologists, translational pharmacologists, and regulatory experts to define target product profiles early and to specify manufacturability constraints that will influence linker and scaffold choices.

Second, investing in supply chain resilience and supplier diversification will mitigate exposure to trade policy shocks and reagent shortages. Strategic sourcing decisions that combine local manufacturing capabilities for critical reagents with validated international partners create redundancy without sacrificing cost-efficiency. Third, pursuit of platform partnerships can accelerate access to complementary capabilities such as high-throughput screening, in vivo pharmacology, or GMP manufacturing; leaders should structure collaborations with clear stage gates and data-sharing protocols to protect strategic optionality.

Finally, organizations should prioritize early regulatory engagement and adopt robust translational validation strategies to build evidentiary packages that support efficient clinical progression. By operationalizing these recommendations-tying discovery design to development constraints, fortifying supply chains, structuring pragmatic partnerships, and engaging regulators proactively-leaders can increase the probability that bicyclic peptide programs reach their therapeutic and commercial potential.

Transparent research methodology explaining how primary interviews, secondary literature, and cross-validation techniques were combined to produce defensible insights on bicyclic peptides

The research underpinning these insights used a curated combination of primary and secondary intelligence to ensure both depth and triangulation. Primary inputs included structured interviews with discovery scientists, translational pharmacologists, procurement leaders, and business development executives directly engaged with constrained peptide modalities. These conversations provided qualitative context on platform capabilities, operational constraints, and partnership rationales. Secondary inputs comprised peer-reviewed literature, patent landscaping, regulatory guidance documents, and technical application notes from platform providers, which were synthesized to validate trends observed in primary discussions.

Analytical methods emphasized cross-validation and reproducibility. Findings reported here were subjected to iterative triangulation across multiple data types and stakeholder perspectives to reduce bias and ensure robust interpretation. Wherever appropriate, methodological caveats are noted to ensure readers understand the assumptions and limits of the evidence base. This approach combines empirical practitioner insight with documented scientific and technical sources to deliver a clear, defensible narrative for decision-makers tasked with advancing bicyclic peptide assets.

Conclusive synthesis that distills strategic imperatives and prioritizes near-term actions to translate bicyclic peptide innovation into clinical progress and commercial outcomes

The collective evidence points to a modality entering a phase of strategic maturation: bicyclic peptides now present a credible option for addressing difficult biological targets, and the ecosystem supporting their discovery and development is sufficiently advanced to support translational progress. Scientific advances in display technologies and linker chemistry, combined with more sophisticated translational toolkits, have reduced some traditional barriers to peptide therapeutics and enabled more targeted program design. At the same time, operational and commercial considerations-such as supply chain resilience, regulatory engagement, and partner design-are increasingly decisive in determining which programs progress.

As stakeholders evaluate the next steps, the prudent course is to adopt an integrated strategy that balances discovery ambition with pragmatic development planning. This includes investing in platform capabilities that demonstrably improve hit quality, structuring partnerships to fill capability gaps without diluting strategic control, and proactively addressing manufacturing and regulatory questions early in the program lifecycle. Organizations that successfully combine scientific rigor with disciplined operational execution will be best positioned to translate bicyclic peptide innovation into patient impact and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bicyclic Peptide Market, by Product Type

  • 8.1. Bicyclic Peptide
    • 8.1.1. Amide Linker
    • 8.1.2. Ester Linker
    • 8.1.3. Thioether Linker
  • 8.2. Linear Peptide
  • 8.3. Monocyclic Peptide
  • 8.4. Multicyclic Peptide

9. Bicyclic Peptide Market, by Therapeutic Area

  • 9.1. Cardiovascular Diseases
  • 9.2. Infectious Diseases
  • 9.3. Inflammatory Disorders
  • 9.4. Oncology

10. Bicyclic Peptide Market, by Technology Platform

  • 10.1. MRNA Display
  • 10.2. Phage Display
  • 10.3. Split-and-Pool
  • 10.4. Yeast Display

11. Bicyclic Peptide Market, by Route Of Administration

  • 11.1. Inhalation
  • 11.2. Injectable
    • 11.2.1. Intramuscular
    • 11.2.2. Intravenous
    • 11.2.3. Subcutaneous
  • 11.3. Oral
  • 11.4. Topical

12. Bicyclic Peptide Market, by Application

  • 12.1. Diagnostics
  • 12.2. Drug Discovery
  • 12.3. Therapeutics
    • 12.3.1. Cardiovascular Diseases
    • 12.3.2. Infectious Diseases
    • 12.3.3. Oncology
      • 12.3.3.1. Hematologic Cancers
      • 12.3.3.2. Solid Tumors

13. Bicyclic Peptide Market, by End User

  • 13.1. Academic & Research Institutes
  • 13.2. Contract Research Organizations
  • 13.3. Pharmaceutical & Biotechnology Companies
    • 13.3.1. Big Pharma
    • 13.3.2. Early-Stage Biotech

14. Bicyclic Peptide Market, by Sales Channel

  • 14.1. Online
  • 14.2. Offline

15. Bicyclic Peptide Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Bicyclic Peptide Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Bicyclic Peptide Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Bicyclic Peptide Market

19. China Bicyclic Peptide Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. Amgen Inc.
  • 20.7. AstraZeneca PLC
  • 20.8. Bicycle Therapeutics plc
  • 20.9. Boehringer Ingelheim International GmbH
  • 20.10. Bristol Myers Squibb Company
  • 20.11. Eli Lilly and Company
  • 20.12. Genentech, Inc.
  • 20.13. GlaxoSmithKline plc
  • 20.14. Johnson & Johnson
  • 20.15. Merck & Co., Inc.
  • 20.16. Novo Nordisk A/S
  • 20.17. PeptiDream Inc.
  • 20.18. Pfizer Inc.
  • 20.19. Sanofi
  • 20.20. Servier Laboratories
  • 20.21. Takeda Pharmaceutical Company Limited
  • 20.22. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BICYCLIC PEPTIDE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BICYCLIC PEPTIDE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA BICYCLIC PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY AMIDE LINKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY AMIDE LINKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY AMIDE LINKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ESTER LINKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ESTER LINKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ESTER LINKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY THIOETHER LINKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY THIOETHER LINKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY THIOETHER LINKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY LINEAR PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY LINEAR PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY LINEAR PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY MONOCYCLIC PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY MONOCYCLIC PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY MONOCYCLIC PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY MULTICYCLIC PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY MULTICYCLIC PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY MULTICYCLIC PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INFLAMMATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INFLAMMATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY MRNA DISPLAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY MRNA DISPLAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY MRNA DISPLAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY PHAGE DISPLAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY PHAGE DISPLAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY PHAGE DISPLAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY SPLIT-AND-POOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY SPLIT-AND-POOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY SPLIT-AND-POOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY YEAST DISPLAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY YEAST DISPLAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY YEAST DISPLAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY HEMATOLOGIC CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY HEMATOLOGIC CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY HEMATOLOGIC CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY BIG PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY BIG PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY BIG PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY EARLY-STAGE BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY EARLY-STAGE BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY EARLY-STAGE BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS BICYCLIC PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. GCC BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GCC BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 248. GCC BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 249. GCC BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. GCC BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 251. GCC BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. GCC BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 253. GCC BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. GCC BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GCC BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 256. GCC BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. G7 BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. G7 BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. G7 BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 287. G7 BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 288. G7 BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. G7 BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 290. G7 BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. G7 BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 292. G7 BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. G7 BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. G7 BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 295. G7 BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. NATO BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. NATO BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. NATO BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 299. NATO BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 300. NATO BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 301. NATO BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. NATO BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 303. NATO BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 304. NATO BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 305. NATO BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. NATO BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. NATO BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 308. NATO BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 309. GLOBAL BICYCLIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA BICYCLIC PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA BICYCLIC PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA BICYCLIC PEPTIDE MARKET SIZE, BY BICYCLIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA BICYCLIC PEPTIDE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA BICYCLIC PEPTIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA BICYCLIC PEPTIDE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA BICYCLIC PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA BICYCLIC PEPTIDE MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA BICYCLIC PEPTIDE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA BICYCLIC PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA BICYCLIC PEPTIDE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA BICYCLIC PEPTIDE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)